Status: Recruiting
Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy
The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.
Participants needed: 33
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Aline Fusco Fares, MDUpdated: Oct 31, 2024Locations: 1
Eligibility criteria
Able to provide a signed Informed Consent Form (ICF), indicating agreement to co... [+16]
Refusal to sign the Informed Consent Form (ICF). [+13]